Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.79
+0.96 (5.70%)
At close: Oct 15, 2026, 4:00 PM EDT
17.85
+0.06 (0.34%)
After-hours: Oct 15, 2026, 7:30 PM EDT
Sarepta Therapeutics Employees
Sarepta Therapeutics had 835 employees as of December 31, 2025. The number of employees decreased by 537 or -39.14% compared to the previous year. That makes Sarepta Therapeutics the 16,197th largest employer in the world and 2,322nd in the United States.
Employees
835
Change (1Y)
-537
Growth (1Y)
-39.14%
Revenue / Employee
$2,364,484
Profits / Employee
-$163,743
Market Cap
1.88B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 835 | -537 | -39.14% |
| Dec 31, 2024 | 1,372 | 58 | 4.41% |
| Dec 31, 2023 | 1,314 | 152 | 13.08% |
| Dec 31, 2022 | 1,162 | 322 | 38.33% |
| Dec 31, 2021 | 840 | -26 | -3.00% |
| Dec 31, 2020 | 866 | 123 | 16.55% |
| Dec 31, 2019 | 743 | 244 | 48.90% |
| Dec 31, 2018 | 499 | 244 | 95.69% |
| Dec 31, 2017 | 255 | 58 | 29.44% |
| Dec 31, 2016 | 197 | -73 | -27.04% |
| Dec 31, 2015 | 270 | 66 | 32.35% |
| Dec 31, 2014 | 204 | 58 | 39.73% |
| Dec 31, 2013 | 146 | 43 | 41.75% |
| Dec 31, 2012 | 103 | 5 | 5.10% |
| Dec 31, 2011 | 98 | 0 | - |
| Dec 31, 2010 | 98 | 35 | 55.56% |
| Dec 31, 2009 | 63 | -20 | -24.10% |
| Dec 31, 2008 | 83 | -42 | -33.60% |
| Dec 31, 2007 | 125 | 8 | 6.84% |
| Dec 31, 2006 | 117 | -6 | -4.88% |
| Dec 31, 2005 | 123 | 11 | 9.82% |
| Dec 31, 2004 | 112 | 6 | 5.66% |
| Dec 31, 2003 | 106 | 17 | 19.10% |
| Dec 31, 2002 | 89 | 4 | 4.71% |
| Dec 31, 2001 | 85 | 14 | 19.72% |
| Dec 31, 2000 | 71 | 15 | 26.79% |
| Dec 31, 1999 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Agios Pharmaceuticals | 540 |
| Maravai LifeSciences Holdings | 415 |
| Vir Biotechnology | 367 |
| UroGen Pharma | 300 |
| Xencor | 260 |
| Zymeworks | 231 |
| Septerna | 123 |
| Mesoblast | 108 |
SRPT News
- 1 day ago - Sarepta presents new preclinical data at 22nd Meeting of OTS on SRP-1003 - TheFly
- 1 day ago - Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting - Business Wire
- 7 days ago - Sarepta price target lowered to $17 from $19 at RBC Capital - TheFly
- 10 days ago - Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT - Business Wire
- 15 days ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - Sarepta presents new data on ELEVIDYS in DMD at WMS Congress - TheFly
- 15 days ago - Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne - Business Wire
- 15 days ago - Sarepta price target lowered to $20 from $23 at JPMorgan - TheFly